Blog: Nestle receives green light on Pfizer deal
Michelle Russell | 6 November 2012
Swiss food group Nestle today (6 November) received approval from the Chinese Ministry of Commerce for its US$11.85bn deal to acquire Pfizer's infant nutrition business.
The approval brings Nestle another step closer to completing the acquisition, which was announced in April this year, enabling the world's largest infant nutrition group to extend its lead in this fast-growing category.
Pfizer Nutrition operates in more than 60 countries globally and 85% of sales are generated in emerging markets, meaning the acquisition effectively fills in the blanks on the map for Nestle. It will provide the company with increased scale in a high-growth, high-margin, category in fast-growing developing markets, CEO Paul Bulcke told investors as it emerged as victor of competitive auction process.
Nestle beat companies including Danone and Mead Johnson to seal the agreement. The next hurdle, however, is to receive approval from anti-trust bodies in several countries in order to fully complete the acquisition.
How can diet-related ill-health be tackled? How can the health and wellbeing of the population improve? Such a complex issue is often reduced to soundbites and brickbats, with industry in the firing l...
Dairy processors in Australia believe the agreement between Canberra and Beijing will make them more competitive in a key export market....
- BRICs: The thinking behind Mondelez's Vietnam deal
- Interview part 1: BRF CFO Augusto Ribeiro
- Prospects for protein: Snacks growth to continue
- Deal or no deal: Should Danone buy Mead Johnson?
- Comment: Why Gardein is Pinnacle's ideal fodder
- 2 Sisters Food Group posts higher annual losses
- Bird flu leads Dutch to stop poultry distribution
- Kellogg trumps Abraaj bid for Bisco Misr
- Arla eyes infant formula firms with lactose plant
- Live blog: Food Matters Live